Blar i forfatter "Naume, Bjørn"

Viser treff 1-10 av 10

    • Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival 

      Morra, Anna; Schreurs, Maartje A. C.; Andrulis, Irene L.; Anton-Culver, Hoda; Augustinsson, Annelie; Beckmann, Matthias W.; Behrens, Sabine; Bojesen, Stig E.; Bolla, Manjeet K.; Brauch, Hiltrud; Broeks, Annegien; Buys, Saundra S.; Camp, Nicola J.; Castelao, Jose E.; Cessna, Melissa H.; Chang-Claude, Jenny; Chung, Wendy K.; Sahlberg, Guro Kristine Kleivi; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Olsen, Karina Standahl; Engebråten, Olav; Naume, Bjørn; Geisler, Jürgen; Grenaker, Grethe Irene; Colonna, Sarah V.; Couch, Fergus J.; Cox, Angela; Cross, Simon S.; Czene, Kamila; Daly, Mary B.; Dennis, Joe; Devilee, Peter; Dörk, Thilo; Dunning, Alison M.; Dwek, Miriam; Easton, Douglas F.; Eccles, Diana M.; Eriksson, Mikael; Evans, D. Gareth; Fasching, Peter A.; Fehm, Tanja N.; Figueroa, Jonine D.; Flyger, Henrik; Gabrielson, Marike; Gago-Dominguez, Manuela; García-Closas, Montserrat; García-Sáenz, José A.; Genkinger, Jeanine; Grassmann, Felix; Gündert, Melanie; Hahnen, Eric; Haiman, Christopher A.; Hamann, Ute; Harrington, Patricia A.; Hartikainen, Jaana M.; Hoppe, Reiner; Hopper, John L.; Houlston, Richard S.; Howell, Anthony; Jakubowska, Anna; Janni, Wolfgang; Jernström, Helena; John, Esther M.; Johnson, Nichola; Jones, Michael E.; Kristensen, Vessela N.; Kurian, Allison W.; Lambrechts, Diether; Le Marchand, Loic; Lindblom, Annika; Lubiński, Jan; Lux, Michael P.; Mannermaa, Arto; Mavroudis, Dimitrios; Mulligan, Anna Marie; Muranen, Taru A.; Nevanlinna, Heli; Nevelsteen, Ines; Neven, Patrick; Newman, William G.; Obi, Nadia; Offit, Kenneth; Olshan, Andrew F.; Park-Simon, Tjoung-Won; Patel, Alpa V.; Peterlongo, Paolo; Phillips, Kelly-Anne; Plaseska-Karanfilska, Dijana; Polley, Eric C.; Presneau, Nadege; Pylkäs, Katri; Rack, Brigitte; Radice, Paolo; Rashid, Muhammad U.; Rhenius, Valerie; Robson, Mark; Romero, Atocha; Saloustros, Emmanouil; Sawyer, Elinor J.; Schmutzler, Rita K.; Schuetze, Sabine; Scott, Christopher; Shah, Mitul; Smichkoska, Snezhana; Southey, Melissa C.; Tapper, William J.; Teras, Lauren R.; Tollenaar, Rob A. E. M.; Tomczyk, Katarzyna; Tomlinson, Ian; Troester, Melissa A.; Vachon, Celine M.; van Veen, Elke M.; Wang, Qin; Wendt, Camilla; Wildiers, Hans; Winqvist, Robert; Ziogas, Argyrios; Hall, Per; Pharoah, Paul D. P.; Adank, Muriel A.; Hollestelle, Antoinette; Schmidt, Marjanka K.; Hooning, Maartje J. (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-07-03)
      Background - Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers.<p> <p>Aim - To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS.<p> <p>Methods - Analyses were based on 82,701 women diagnosed with a first ...

    • Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study 

      Synnestvedt, Marit; Borgen, Elin; Wist, Erik; Wiedswang, Gro; Weyde, Kjetil; Risberg, Terje; Kersten, Christian; Mjaaland, Ingvil; Vindi, Lise; Schirmer, Cecilie; Nesland, Jahn M; Naume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-12-22)
      Background: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) after completion of systemic adjuvant treatment predicts reduced survival in breast cancer. The present study explores the use of DTCs to identify adjuvant insufficiently treated patients to be offered secondary adjuvant treatment intervention, and as a surrogate marker for therapy response.<p> <p>Methods: A total of ...

    • The impact of coding germline variants on contralateral breast cancer risk and survival 

      Morra, Anna; Mavaddat, Nasim; Muranen, Taru A.; Ahearn, Thomas U.; Allen, Jamie; Andrulis, Irene L.; Auvinen, Päivi; Becher, Heiko; Behrens, Sabine; Blomqvist, Carl; Bojesen, Stig E.; Bolla, Manjeet K.; Brauch, Hiltrud; Camp, Nicola J.; Carvalho, Sara; Castelao, Jose E.; Cessna, Melissa H.; Chang-Claude, Jenny; Chenevix-Trench, Georgia; Sahlberg, Guro Kristine Kleivi; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Olsen, Karina Standahl; Engebråten, Olav; Naume, Bjørn; Geisler, Jürgen; Grenaker, Grethe Irene; Czene, Kamila; Decker, Brennan; Dennis, Joe; Dörk, Thilo; Dorling, Leila; Dunning, Alison M.; Ekici, Arif B.; Eriksson, Mikael; Evans, D. Gareth; Fasching, Peter A.; Figueroa, Jonine D.; Flyger, Henrik; Gago-Dominguez, Manuela; García-Closas, Montserrat; Geurts-Giele, Willemina R.R.; Giles, Graham G.; Guénel, Pascal; Gündert, Melanie; Hahnen, Eric; Hall, Per; Hamann, Ute; Harrington, Patricia A.; He, Wei; Heikkilä, Päivi; Hooning, Maartje J.; Hoppe, Reiner; Howell, Anthony; Humphreys, Keith; Kristensen, Vessela N.; Mannermaa, Arto; Manoochehri, Mehdi; Manoukian, Siranoush; Margolin, Sara; Mavroudis, Dimitrios; Milne, Roger L.; Mulligan, Anna Marie; Newman, William G.; Park-Simon, Tjoung-Won; Peterlongo, Paolo; Pharoah, Paul D.P.; Rhenius, Valerie; Saloustros, Emmanouil; Sawyer, Elinor J.; Schmutzler, Rita K.; Shah, Mitul; Spurdle, Amanda B.; Tomlinson, Ian; Truong, Thérèse; van Veen, Elke M.; Vreeswijk, Maaike P.G.; Wang, Qin; Wendt, Camilla; Yang, Xiaohong R.; Nevanlinna, Heli; Devilee, Peter; Easton, Douglas F.; Schmidt, Marjanka K. (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-02-23)
      Evidence linking coding germline variants in breast cancer (BC)-susceptibility genes other than BRCA1, BRCA2, and CHEK2 with contralateral breast cancer (CBC) risk and breast cancer-specific survival (BCSS) is scarce. The aim of this study was to assess the association of protein-truncating variants (PTVs) and rare missense variants (MSVs) in nine known (ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, ...

    • LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer 

      Sas-Chen, Aldema; Aure, Miriam Ragle; Leibovich, Limor; Carvalho, Silvia; Enuka, Yehoshua; Körner, Cindy; Polycarpou-Schwarz, Maria; Lavi, Sara; Nevo, Nava; Kuznetsov, Yuri; Yuan, Justin; Azuaje, Francisco; Ulitsky, Igor; Diederichs, Sven; Wiemann, Stefan; Yakhini, Zohar; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Yarden, Yosef; Sauer, Torill; Geisler, Jürgen; Hofvind, Solveig; Bathen, Tone Frost; Borgen, Elin; Engebråten, Olav; Fodstad, Øystein; Garred, Øystein; Geitvik, Gry; Kåresen, Rolf; Naume, Bjørn; Mælandsmo, Gunhild; Russnes, Hege Elisabeth Giercksky; Schlichting, Ellen; Sørlie, Therese; Lingjærde, Ole Christian; Sahlberg, Kristine Kleivi; Skjerven, Helle; Fritzman, Britt (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-09-01)
      Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal-like subtype associates with increased EGFR signaling, while another, the HER2-enriched subtype, engages a kin of EGFR Based on the premise that EGFR-regulated lncRNAs might ...

    • Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen 

      Helland, Thomas; Naume, Bjørn; Hustad, Steinar; Bifulco, Ersilia; Kvaløy, Jan Terje; Sætersdal, Anna Barbro; Synnestvedt, Marit; Lende, Tone Hoel; Gilje, Bjørnar; Mjaaland, Ingvil; Weyde, Kjetil; Blix, Egil Støre; Wiedswang, Gro; Borgen, Elin; Hertz, Daniel Louis; Janssen, Emiel; Mellgren, Gunnar; Søiland, Håvard (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-12-14)
      Abstract Low steady‐state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast cancer (BC) patients receiving adjuvant tamoxifen as initial treatment, we have associated our previously reported thresholds for the two active metabolites, Z‐endoxifen and Z‐4‐hydroxy‐tamoxifen (Z‐4OHtam), ...

    • Ny medikamentell behandling av brystkreft - Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft 

      Johansen, Karianne; Lønning, Per Eystein; Naume, Bjørn; Norderhaug, Inger Natvig; Norum, Jan; Olsen, Jan Abel; Wist, Erik (Research report; Forskningsrapport, 2006)
      Denne rapporten er første del av et oppdrag fra Sosial- og helsedirektoratet og RHF - fagdirektørene med fokus på effekt og bivirkninger av virkestoffet trastuzumab ved adjuvant behandling av brystkreft. Trastuzumab er ofte omtalt ved produktnavnet Herceptin.

    • Ny medikamentell behandling av brystkreft Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft - en helseøkonomisk analyse 

      Johansen, Karianne; Wisløff, Torbjørn; Kristiansen, Ivar Sønbø; Lønning, Per Eystein; Naume, Bjørn; Norum, Jan; Norderhaug, Inger Natvig; Olsen, Jan Abel; Wist, Erik (Research report; Forskningsrapport, 2006)
      Denne rapporten er andre del av et oppdrag fra Sosial- og helsedirektoratet og RHF - fagdirektørene med fokus på virkestoffet trastuzumab ved adjuvant behandling av brystkreft. Adjuvant behandling gis i tillegg til hovedbehandlingen (for eksempel kirurgi) for å påvirke eventuelt gjenværende kreftceller hos pasienten. Denne delen av oppdraget vurderer de helseøkonomiske konsekvensene av adjuvant ...

    • Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival 

      Mathiesen, Randi Margit Ruud; Borgen, Elin; Renolen, Anne; Løkkevik, Erik; Nesland, Jahn M; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Kvalheim, Gunnar; Lønning, Per Eystein; Naume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-08-14)
      <i>Introduction</i> - Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and to evaluate their ...

    • Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer 

      Egeland, Eivind Valen; Pedersen, Kjetil Boye; Park, Daehoon; Synnestvedt, Marit; Sauer, Torill; The Oslo Breast Cancer Consortium (OSBREAC); Naume, Bjørn; Borgen, Elin; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-01-05)
      Purpose: <br> Prognostic factors are useful in order to identify early-stage breast cancer patients who might benefit from adjuvant treatment. The metastasis-promoting protein S100A4 has previously been associated with poor prognosis in breast cancer patients. The protein is expressed in diverse subcellular compartments, including the cytoplasm, extracellular space, and nucleus. Nuclear expression ...

    • Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers 

      Haugen, Mads Haugland; Lingjærde, Ole Christian; Hedenfalk, Ingrid; Garred, Øystein; Borgen, Elin; Loman, Niklas; Hatschek, Thomas; Børresen-Dale, Anne-Lise; Naume, Bjørn; Mills, Gordon B.; Mælandsmo, Gunhild Mari; Engebråten, Olav (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01-28)
      <p>PURPOSE: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. <p>PATIENTS AND METHODS: In the NeoAva phase II clinical trial, patients (N = 132) with large (≥ 25 mm) human epidermal growth factor receptor 2 (HER2)-negative primary tumors were randomly ...